Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open- label, phase 3 trial - The Lancet
Five cancer drugs back on NHS list after deals with drug companies | The BMJ
ICD-9/10 codes to define serious adverse events for Bevacizumab based... | Download Scientific Diagram
Genentech: Statements | Genentech Statement on Counterfeit Drug Labeled as Avastin® (Bevacizumab) in the United States
Avastin Injections Are Said to Cause Blindness - The New York Times
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study - The Lancet Oncology
Avastin - FDA prescribing information, side effects and uses
avastin - Diabetic Retinopathy
![PDF] Off-label use of bevacizumab for wet age-related macular degeneration in Europe | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/dd8a688b93d7c74f55bbed645b027d6775de792f/6-Table1-1.png "PDF] Off-label use of bevacizumab for wet age-related macular degeneration in Europe | Semantic Scholar")
PDF] Off-label use of bevacizumab for wet age-related macular degeneration in Europe | Semantic Scholar
PDF) Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Bevacizumab-awwb becomes first biosimilar approved for cancer treatment | MDedge Hematology and Oncology
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer - Journal of Thoracic Oncology
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial - The Lancet Gastroenterology & Hepatology
Immunotherapy Regimen Approved for Hepatocellular Carcinoma - MPR
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial - European Journal of Cancer
Avastin disappoints against ovarian cancer | KCBY
Avastin
Avastin's breast cancer use to continue in Europe | Pharmafile
PDF) Bevacizumab: Off-label use in ophthalmology
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology
NHS wins legal fight against pharma firms over sight-loss drug | NHS | The Guardian
NHS wins legal fight with pharma over off-label Avastin - PMLiVE
